AR047536A1 - Moduladores del receptor de quimioquina ccr5 - Google Patents

Moduladores del receptor de quimioquina ccr5

Info

Publication number
AR047536A1
AR047536A1 ARP050100437A ARP050100437A AR047536A1 AR 047536 A1 AR047536 A1 AR 047536A1 AR P050100437 A ARP050100437 A AR P050100437A AR P050100437 A ARP050100437 A AR P050100437A AR 047536 A1 AR047536 A1 AR 047536A1
Authority
AR
Argentina
Prior art keywords
alkyl
aryl
heteroaryl
cycloalkyl
independently
Prior art date
Application number
ARP050100437A
Other languages
English (en)
Inventor
David Mark Rotstein
Stephen Deems Gabriel
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of AR047536A1 publication Critical patent/AR047536A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4747—Quinolines; Isoquinolines spiro-condensed
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/537—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines spiro-condensed or forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • AIDS & HIV (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

utiles en el tratamiento de una variedad de trastornos, incluyendo aquellos en que la modulacion de los receptores CCR5 está implicada. Los trastornos que se pueden tratar o prevenir mediante los presentes derivados incluyen VIH e infecciones retrovirales genéticamente relacionadas (y el resultante síndrome de inmunodeficiencia adquirida, SIDA), enfermedades del sistema inmune y enfermedades inflamatorias. Reivindicacion 1: Un compuesto de acuerdo con la formula (1), en donde: R2 es un grupo de formulas (2), A es (CH2)q; R1 es C(=O)R4, S(O)pR4, o C(=O)X, en donde X es NR5R6 o OR11; R2a y R2b son a) independientemente hidrogeno, C1-10 alquilo, C2-10 alquenilo, C1-10 haloalquilo, C3-7 cicloalquilo, (C3-7)cicloalquil-(C1-3)alquilo, C1-10 heteroalquilo, C1-10 alquilideno, C1-10 heteroalquilideno, arilo, aril-(C1-3)alquilo, heteroarilo, heteroaril-(C1-3)alquilo, C1-10 alquilo en donde 2 o 3 átomos de carbono no adyacentes son reemplazados independientemente con -O-, -S-, -NH- o - (CH2)wR8 en donde w es un numero entero de 2 a 6, y la cadena C2-6 alquileno opcionalmente contiene un doble enlace, -(CH2)wCH=NR9 en donde w es un numero entero de 2 a 6; o b) junto con los átomos de carbono a los que están unidos, son o-fenileno opcionalmente sustituido con 1 a 3 sustituyentes independientemente seleccionados del grupo consistente de C1-6 alquilo, C1-6 haloalquilo, C1-6 alcoxilo, C1-6 tioalquilo, C1-6 alquilsulfonilo, halogeno, NR5aR6a, ciano y nitro con la condicion que si R2a, R2b, junto con los átomos de carbono a los que están unidos son o-fenileno opcionalmente sustituido, m es 1; R3 es C1-10 alquilo, C2-10 alquenilo, C1-10 heteroalquilo, C3-7 cicloalquilo, C1-6 alquilheterociclo, arilo, aril-(C1-3)alquilo, heteroarilo, C1-6 alquil heteroarilo, C(=O)R3a en donde R3a es C1-10 alquilo, C2-10 alquenilo o C3-7 cicloalquilo, o un fragmento de grupo de formulas (3), R4 es C1-10 alquilo, C3-7 cicloalquil-(C1-10)alquilo sustituido, heterociclo, arilo, o heteroarilo; R5 y R6 son a) H, C1-10 alquilo, C1-10 heteroalquilo, C3-7 cicloalquilo, (C1-6)alquil-(C3-7)cicloalquilo, heterociclo-(C1-6)alquilo, arilo, aril-(C1-3)alquilo, heteroarilo, C1-6 alquil heteroarilo cuando se cogen independientemente; o b) C3-6 alquileno o [(CH2)]2O cuando son cogidos juntos; R5a y R6a son a) hidrogeno, C1-6 alquilo o C1-6 alquilcarbonilo cuando se cogen independientemente o b) C3-6 alquileno o [(CH2)]2O cuando se cogen juntos; R7 es hidrogeno, ciano o C1-6 alquilo; R8 es -CN, -NO2, -CONR5aR6a, COR9, -NHSO2(C1-6)alquilo; R9 es OH o C1-6 alcoxilo; R10 es N o N+-O-; R11 es C1-10 alquilo, C1-10 heteroalquilo, C3-7 cicloalquilo, (C1-6)alquil-(C3-7)cicloalquil, heterociclo-(C1-6)alquilo, arilo, aril-(C1- 3)alquilo, heteroarilo (C1-6)alquil-heteroarilo; m es 0 o 1; n es independientemente 0 a 2; o es independientemente 0 o 1; p es 0 a 2; q es 1 a 3; en donde: cada dicho heteroarilo se selecciona independientemente del grupo consistente de piridilo, 1- oxi-piridinilo, pirimidilo, oxipirimidinilo, pirazinilo, piridazinilo, pirrolilo, tienilo, furilo, imidazolilo, pirazolilo, oxazolilo, tiazolilo, isoxazolilo, isotiazolilo, indolinilo, N-Boc-indolinilo, quinolinilo, isoquinoli-nilo, benzofuranilo, 4,5,6,7-tetrahidrobenzofuranilo y 1,2,3,4-tetrahidroacridinilo; cada dicho arilo y dicho heteroarilo están opcionalmente independientemente sustituidos con 1 a 3 sustituyentes seleccionados del grupo consistente de hidroxilo, C1-6 alquilo, C1-6 haloalquilo, C1-6 alcoxilo, C1-6 haloalcoxilo, C1-6 tioalquilo, arilo, aril-(C1-3)alquilo, ariloxilo, heteroariloxilo, tioarilo, tioheteroarilo, aril-(C1-3)alcoxilo, heteroarilo, heterociclilo, C1-6 alquilheterociclo, C1-6 alquilsulfonilo, -NHSO2(C1- 6)alquilo, SO2NR5aR6a, (CH2)uCO2R9, (CH2)uCONR5aR6a, -X1C(=O)X2, C1-10 alquilcarbonilo, halogeno, NR5aR6a, ciano, nitro y C1-10 alquilo en donde 2 o 3 átomos de carbono no adyacentes son reemplazados independientemente con -O-, -S-, -NH- o NR5, en donde u es un numero entero de 0 a 6, X1 es NR6b o O; X2 es NR5R6 o OR3 y R5b es H o C1-6 alquilo; cada dicho heterociclo se selecciona independientemente del grupo consistente de pirrolidinilo, 1-metil-pirrolidinilo, piperidinilo, morfolinilo, tiomorfolinilo, tetrahidrofuranilo, dioxolanilo y piranilo opcionalmente sustituido con 1 a 3 sustituyentes independientemente seleccionados del grupo consistente de hidroxi-(C1-6)alquilo, C1-6 haloalquilo, C1-6 alcoxilo, C1-6 tioalquilo, C1-6 alquilsulfonilo, halogeno, NR5R6a, ciano y nitro; enantiomeros puros, enantiomeros parcialmente resueltos, mezclas racémicas, sales de adicion ácida farmacéuticamente aceptables, hidratos y solvatos de los mismos.
ARP050100437A 2004-02-10 2005-02-08 Moduladores del receptor de quimioquina ccr5 AR047536A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US54340804P 2004-02-10 2004-02-10

Publications (1)

Publication Number Publication Date
AR047536A1 true AR047536A1 (es) 2006-01-25

Family

ID=34837578

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP050100437A AR047536A1 (es) 2004-02-10 2005-02-08 Moduladores del receptor de quimioquina ccr5

Country Status (15)

Country Link
US (2) US7332500B2 (es)
EP (1) EP1716156A2 (es)
JP (1) JP2007522160A (es)
KR (1) KR100863854B1 (es)
CN (1) CN100497346C (es)
AR (1) AR047536A1 (es)
AU (1) AU2005211499A1 (es)
BR (1) BRPI0507586A (es)
CA (1) CA2554671A1 (es)
CO (1) CO5700742A2 (es)
IL (1) IL176720A0 (es)
NO (1) NO20063495L (es)
RU (1) RU2006132465A (es)
TW (1) TW200529857A (es)
WO (1) WO2005075484A2 (es)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6374762B1 (en) * 1997-10-27 2002-04-23 Correct Craft, Inc. Water sport towing apparatus
CN101031296A (zh) * 2004-08-19 2007-09-05 弗特克斯药品有限公司 毒蕈碱受体调节剂
US7786141B2 (en) * 2004-08-19 2010-08-31 Vertex Pharmaceuticals Incorporated Dihydrospiroindene modulators of muscarinic receptors
CN101155587A (zh) * 2004-11-29 2008-04-02 弗特克斯药品有限公司 毒蕈碱受体调节剂
NZ556629A (en) * 2005-03-03 2010-04-30 Janssen Pharmaceutica Nv Substituted oxa-diaza-spiro-[5.5]-undecanone derivatives and their use as neurokinin antagonists
BRPI0608847A2 (pt) 2005-03-08 2010-02-02 Janssen Pharmaceutica Nv derivados de diaza-espiro-[4,4]-nonano substituìdos e seu uso como antagonistas de neurocinina
WO2007045573A1 (en) 2005-10-19 2007-04-26 F. Hoffmann-La Roche Ag Phenyl-acetamide nnrt inhibitors
CN101374519A (zh) * 2005-12-22 2009-02-25 弗特克斯药品有限公司 毒蕈碱性受体调节剂
RU2008137593A (ru) 2006-02-22 2010-03-27 Вертекс Фармасьютикалз Инкорпорейтед (Us) Модуляторы мускариновых рецепторов
AU2007221220A1 (en) * 2006-02-22 2007-09-07 Vertex Pharmaceuticals Incorporated Spiro condensed piperidnes as modulators of muscarinic receptors
US7858790B2 (en) * 2006-06-29 2010-12-28 Vertex Pharmaceuticals Incorporated Modulators of muscarinic receptors
JP2010500412A (ja) * 2006-08-15 2010-01-07 バーテックス ファーマシューティカルズ インコーポレイテッド ムスカリン受容体の調節剤
ATE503744T1 (de) 2006-08-16 2011-04-15 Hoffmann La Roche Nicht-nukleosidische reverse-transkriptase-hemmer
EP2051715A2 (en) 2006-08-18 2009-04-29 Vertex Pharmceuticals Incorporated Modulators of muscarinic receptors
KR101475091B1 (ko) 2006-12-13 2014-12-22 에프. 호프만-라 로슈 아게 비뉴클레오시드 역전사 효소 억제제로서 2-(피페리딘-4-일)-4-페녹시- 또는 페닐아미노-피리미딘 유도체
EP2128163A1 (en) * 2007-01-25 2009-12-02 Takeda Pharmaceutical Company Limited Spiro-ring compound
EP2142555A1 (en) * 2007-03-29 2010-01-13 F. Hoffmann-Roche AG Heterocyclic antiviral compounds
US7977358B2 (en) * 2007-07-26 2011-07-12 Hoffmann-La Roche Inc. Pyrazol derivatives
WO2009037168A1 (en) * 2007-09-19 2009-03-26 F. Hoffmann-La Roche Ag Heterocyclic antiviral compounds
WO2009045519A1 (en) * 2007-10-03 2009-04-09 Vertex Pharmaceuticals Incorporated Modulators of muscarinic receptors
EP2285807A1 (en) * 2008-05-09 2011-02-23 F. Hoffmann-La Roche AG Heterocyclic antiviral compounds
EP2440251A4 (en) 2009-06-09 2013-01-16 Defyrus Inc INTERFERON ADMINISTRATION FOR PROPHYLAXIS AGAINST PATHOGEN INFECTION OR TREATMENT OF PATHOGEN INFECTION
WO2012171863A1 (en) * 2011-06-16 2012-12-20 Boehringer Ingelheim International Gmbh New selective ccr2 antagonists
JP6083818B2 (ja) 2011-11-18 2017-02-22 ヘプタレス セラピューティクス リミテッドＨｅｐｔａｒｅｓ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｌｉｍｉｔｅｄ ムスカリンｍ１受容体アゴニスト
GB201404922D0 (en) 2014-03-19 2014-04-30 Heptares Therapeutics Ltd Pharmaceutical compounds
LT3377500T (lt) * 2015-11-16 2022-12-12 Esteve Pharmaceuticals, S.A. Oksadiazaspiro junginiai, skirti piktnaudžiavimo narkotikais arba priklausomybės nuo jų gydymui
GB201617454D0 (en) 2016-10-14 2016-11-30 Heptares Therapeutics Limited Pharmaceutical compounds
TW201922758A (zh) 2017-10-24 2019-06-16 美商歐樂根公司 烯胺及烯胺的非鏡像選擇性還原
GB201810239D0 (en) 2018-06-22 2018-08-08 Heptares Therapeutics Ltd Pharmaceutical compounds
WO2020048826A1 (en) 2018-09-03 2020-03-12 Bayer Aktiengesellschaft 5-substituted 1-oxa-3,9-diazaspiro[5.5]undecan-2-one compounds
WO2020048828A1 (en) 2018-09-03 2020-03-12 Bayer Pharma Aktiengesellschaft 5-heteroaryl-3,9-diazaspiro[5.5]undecane compounds
WO2020048827A1 (en) 2018-09-03 2020-03-12 Bayer Aktiengesellschaft 1, 3, 9-triazaspiro[5.5] undecan-2-one compounds
GB201819960D0 (en) 2018-12-07 2019-01-23 Heptares Therapeutics Ltd Pharmaceutical compounds
US11629196B2 (en) 2020-04-27 2023-04-18 Incelldx, Inc. Method of treating SARS-CoV-2-associated hypercytokinemia by administering a human monoclonal antibody (PRO-140) that inhibits CCR5/CCL5 binding interactions

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL127065C (es) * 1964-04-22
HU204529B (en) * 1989-08-10 1992-01-28 Richter Gedeon Vegyeszet Process for producing new 1-oxa-2-oxo-8-aza-spiro(4,5)decane derivatives and pharmaceutical compositions containing them
CA2233204A1 (en) 1995-09-29 1997-04-03 Joseph A. Jakubowski Spiro compounds as inhibitors of fibrinogen-dependent platelet aggregation
US6689765B2 (en) * 1999-05-04 2004-02-10 Schering Corporation Piperazine derivatives useful as CCR5 antagonists
JP3722700B2 (ja) * 1999-05-04 2005-11-30 シェーリング コーポレイション Ｃｃｒ５アンタゴニストとして有用なピペラジン誘導体
US6391865B1 (en) * 1999-05-04 2002-05-21 Schering Corporation Piperazine derivatives useful as CCR5 antagonists
ES2246233T3 (es) 1999-05-04 2006-02-16 Schering Corporation Derivados de piperidina utiles como antagonistas de ccr5.
MXPA02005465A (es) 1999-12-03 2003-10-15 Ono Pharmaceutical Co Derivados de triazaspiro(5.5)undecano y composiciones farmaceuticas que los comprenden, como un ingrediente activo.
AU2001230537A1 (en) 2000-02-01 2001-08-14 Daiichi Pharmaceutical Co., Ltd. Pyridoxazine derivatives
AU2001243394A1 (en) * 2000-03-02 2001-09-12 Smith Kline Beecham Corporation Compounds and methods
CA2447329C (en) * 2001-05-14 2009-07-28 F.Hoffmann-La Roche Ag 1-oxa-3,9-diaza-spiro[5,5]undecan-2-ones derivatives and its use as antagonist of the neurikinin receptor
NZ571695A (en) * 2001-12-28 2010-02-26 Acadia Pharm Inc Spiroazacyclic compounds as monoamine receptor for modulating 5-HT2A receptor-mediated events

Also Published As

Publication number Publication date
US7538122B2 (en) 2009-05-26
KR100863854B1 (ko) 2008-10-15
EP1716156A2 (en) 2006-11-02
BRPI0507586A (pt) 2007-07-03
AU2005211499A1 (en) 2005-08-18
CN100497346C (zh) 2009-06-10
CA2554671A1 (en) 2005-08-18
KR20060108770A (ko) 2006-10-18
CO5700742A2 (es) 2006-11-30
IL176720A0 (en) 2006-10-31
TW200529857A (en) 2005-09-16
NO20063495L (no) 2006-11-01
JP2007522160A (ja) 2007-08-09
US7332500B2 (en) 2008-02-19
US20080139544A1 (en) 2008-06-12
RU2006132465A (ru) 2008-03-20
WO2005075484A3 (en) 2005-10-20
WO2005075484A2 (en) 2005-08-18
US20050176703A1 (en) 2005-08-11
CN1918171A (zh) 2007-02-21

Similar Documents

Publication Publication Date Title
AR047536A1 (es) Moduladores del receptor de quimioquina ccr5
MX2023002195A (es) Compuestos y metodos para el tratamiento de infecciones virales.
RU2018121499A (ru) Гипоксантины в качестве ингибиторов убиквитин-специфической протеазы 1
EA200970493A1 (ru) Макроциклические ингибиторы вируса гепатита с
AR047063A1 (es) Heterociclos azabiciclicos como moduladores de receptor canabinoide
AR078622A1 (es) Piperidinas sustituidas que aumentan la actividad de p53 y sus usos
PE20081362A1 (es) DERIVADOS MORFOLINO PIRIMIDINA COMO INHIBIDORES DE mTOR QUINASA Y PI3K
PE20080998A1 (es) Derivados de pirazol como inhibidores del sistema enzimatico cyp450
UY29177A1 (es) Derivados sustituidos de purina, purinona y deazapurina, composiciones que los contienen métodos para su preparación y sus usos
PE20141827A1 (es) Inhibidores de proteinas quinasas
PE20091116A1 (es) Derivados de piridina y pirazina como inhibidores de tirosina quinasas
PE20081658A1 (es) Derivados indolicos con anillo unido en las posiciones 5,6 y sus metodos de uso
UY29068A1 (es) Inhibidores de la arn polimerasa dependiente de arn del virus de la hepatitis c y composiciones y tratamientos que los usan
AR035665A1 (es) Imidazoquinolinas y 6,7,8,9-tetrahidroimidazoquinolinas, composiciones farmaceuticas que las comprenden, uso de dichos compuestos en la preparacion de medicamentos, e intermediarios utiles en la sintesis de dichos compuestos
NO20072235L (no) HCV-hemmende bicykliske pyrimidiner
ECSP088324A (es) 2-amino-7,8-dihidro-6h-pirido[4,3-d]pirimidina-5-onas
PE20080772A1 (es) Nuevos derivados de bipiridina sustituidos y su uso
NO20070336L (no) Indolderivater som histamin-reseptorantagonister
RU2014124640A (ru) Производные аминопиримидина в качестве модуляторов богатой лейцином повторной киназы 2 (lrrk2)
BRPI0508321A (pt) hidróxi-6-heteroarilfenantridinas e seu uso como inibidores de pde4
AR099498A1 (es) Compuestos de triazina y su uso farmacéutico
PE20120593A1 (es) Derivados fusionados de pirimidin-4-ona como antagonistas del receptor de angiotensina ii y como agonistas del receptor ppar gamma
PE20090741A1 (es) Derivados de 1,1,1-trifluor-2-hidroxi-3-fenilpropano
UY27503A1 (es) Nuevos derivados de piperazina
ES2630079T3 (es) Moduladores de la ruta del complemento y usos de los mismos

Legal Events

Date Code Title Description
FB Suspension of granting procedure